Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CSL Of Australia Raises Equity Funds Ahead of U.S. Merger Approval

This article was originally published in PharmAsia News

Executive Summary

Australia's CSL drug maker has gone ahead with assertive equity-raising efforts even though the U.S. Federal Trade Commission could still block its planned $3.5 billion acquisition of Talecris Biotherapeutics. In less than a week after the deal was announced, CSL raised $1.53 billion to buy the firm from its owners, Cerberus Partners and Ampersand Ventures. Some analysts believe the FTC will order some divestments of human plasma products before approving the merger. One problem could be Talecris's Gamunex, with has a 24 percent market share, the same as CSL and its own products, amounting to a combined 48 percent compared with Baxter International's market-leading 35 percent. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts